What is Dermatofibrosarcoma Protuberans (DFSP)?

Dermatofibrosarcoma protuberans, or DFSP, is a rare skin sarcoma. It often grows slowly and can invade nearby tissue. Many cases start as a firm patch or raised lump. Diagnosis usually depends on a skin biopsy and pathology review. Treatment conversations often focus on surgery and preventing local recurrence. Some situations involve radiation or targeted therapy. A clinician can explain how DFSP differs from other soft tissue tumors.

What records help when reviewing DFSP diagnosis details?

Helpful records include the biopsy pathology report and any procedure notes. Look for sections on histology, margin status, and immunostains like CD34. If performed, genetic results may mention a COL1A1-PDGFB fusion. Imaging reports, such as MRI, can add context for deeper involvement. If using telehealth, uploading clear scans helps the clinician review details efficiently. Keep dates attached to each document for easier timeline review.

How are DFSP treatment options usually discussed?

Clinicians often start with surgery terms and goals. Common options include wide local excision and Mohs micrographic surgery for select sites. Discussions may cover reconstruction, margin assessment, and the chance of recurrence. Radiation therapy may be considered in certain scenarios, such as difficult margins. Targeted therapy, including imatinib, may come up for unresectable, recurrent, or metastatic disease. The final plan depends on tumor location, prior treatment, and specialist input.

Can Medispress telehealth help with DFSP questions?

Telehealth can be useful for organizing records and clarifying terminology. Visits take place by video in a secure app, and clinicians lead clinical decisions. A visit may help review biopsy language, imaging summaries, and follow-up questions. Some needs still require in-person care, such as surgery planning or urgent wound concerns. When clinically appropriate, a provider may coordinate prescription options through partner pharmacies, based on state requirements.

What does "CD34 positive" mean on a DFSP report?

CD34 is a protein marker that pathologists can detect with staining. Many DFSP tumors show CD34 positivity, which can support the diagnosis. It is not fully specific, so it must match the microscope pattern and clinical story. Some reports also include molecular testing, like COL1A1-PDGFB fusion, to strengthen classification. A clinician or pathologist can explain how all findings fit together and what details matter most for planning.

Dermatofibrosarcoma Protuberans

Care Options for Dermatofibrosarcoma Protuberans

This category page collects practical information on Dermatofibrosarcoma Protuberans, often called DFSP.

It is a rare soft tissue sarcoma of the skin. It often grows slowly, but can spread locally. Many people first notice a firm plaque or raised nodule. This browse page focuses on common terms, care pathways, and access basics.

Use this page to compare resources and understand what clinicians may review. Examples include biopsy wording, imaging notes, and follow-up planning after treatment. The goal is clearer conversations and less paperwork stress.

Visits are provided by licensed U.S. clinicians.

Dermatofibrosarcoma Protuberans What You’ll Find

Listings and education on this page usually center on diagnosis language and care planning. DFSP discussions often start with a skin exam and a biopsy report. You may also see plain-language explainers that translate pathology terms into everyday wording.

Because Dermatofibrosarcoma Protuberans can resemble benign skin growths, the details matter. A report may mention dermatofibrosarcoma protuberans histology (microscope features) and CD34 positive DFSP (a marker seen on many tumor cells). Some reports also reference the COL1A1 PDGFB fusion, a gene change linked to DFSP.

Resources may also cover dermatofibrosarcoma protuberans differential diagnosis, which means “what else it could be.” Clinicians may compare it with scars, keloids, dermatofibromas, or other spindle-cell tumors. Some pages discuss DFSP imaging and DFSP staging when deeper spread is a concern.

Dermatofibrosarcoma protuberans overview in plain language
Dermatofibrosarcoma protuberans symptoms and typical skin changes
Dermatofibrosarcoma protuberans causes, including key genetic findings
Dermatofibrosarcoma protuberans diagnosis basics and biopsy terms
Surgical terms like wide local excision DFSP and Mohs micrographic surgery DFSP
Non-surgical options such as radiation therapy DFSP and imatinib therapy DFSP
DFSP recurrence and follow up planning concepts
Notes on pediatric dermatofibrosarcoma protuberans and pigmented DFSP Bednar tumor

How to Choose

This condition category can include both educational content and access-related listings. Choosing what to read first gets easier with a simple checklist. Start with the documents already available, then fill the gaps.

Match resources to the records already in hand

Look for content that explains biopsies and margin status in clear terms.
Prioritize pages that define CD34, spindle cells, and “infiltrative” growth.
Check whether a resource covers genetics, like COL1A1-PDGFB fusion results.
Use imaging explainers if MRI or CT is mentioned in the plan.
Note whether the resource distinguishes primary DFSP from recurrent disease.
Include pediatric-focused materials when the patient is a child or teen.

Quick tip: Keep dated photos of the skin change for reference.

Use questions that support shared decision-making

Many decisions depend on location, size, and prior procedures. A clinician may also consider cosmetic and functional outcomes. The questions below keep the discussion organized and specific.

Which parts of the pathology report drive the working diagnosis?
Do margins look clear, close, or involved on the report?
Is Mohs micrographic surgery DFSP being considered for this site?
When is wide local excision DFSP the more typical approach?
Are there reasons to discuss radiation therapy DFSP after surgery?
In what situations does targeted therapy DFSP come up in discussions?
What follow-up schedule is typical after treatment for recurrence monitoring?

Term seen on reports	What it usually refers to
Core or punch biopsy	Small tissue sample taken to confirm a diagnosis
CD34 positive	Marker pattern that often supports DFSP with the right histology
COL1A1-PDGFB fusion	Gene change that can support DFSP classification
Margins	Whether tumor reaches the edge of the removed tissue

Appointments run by video in a secure, HIPAA-compliant app.

Safety and Use Notes

DFSP information online can feel uneven and sometimes alarming. It helps to separate what is confirmed from what is suspected. “Sarcoma” signals a cancer type, but DFSP often behaves differently than deep soft tissue sarcomas.

For Dermatofibrosarcoma Protuberans, clinicians commonly focus on local control and recurrence risk. That makes the pathology details and procedure notes important over time. Keep copies of the biopsy report, operative note, and final margin status when available.

When treatment options are discussed, they may include surgery, radiation, and targeted medicines. For example, imatinib therapy DFSP is a targeted therapy used in specific situations. Every medicine has risks and interactions, so a clinician reviews the full medication list.

Bring a current medication list, including supplements and over-the-counter products.
Ask how to recognize infection or wound issues after a procedure.
Clarify which symptoms should be handled urgently versus at a routine visit.
Confirm who coordinates follow-up when multiple specialists are involved.

Why it matters: Clear follow-up plans can reduce missed signs of recurrence.

Access and Prescription Requirements

Some options discussed for DFSP require prescriptions and pharmacy dispensing. A prescription generally requires a clinician evaluation and appropriate documentation. Depending on the situation, this may include pathology confirmation or specialist notes.

Access steps often depend on where the patient is in the care pathway. Early on, the key need is a confirmed dermatofibrosarcoma protuberans diagnosis, usually through biopsy. Later, the focus shifts to post-procedure care, symptom support, or oncology-directed medicines when indicated.

Medispress can support cash-pay access, often without insurance, when appropriate. Prescription processing also includes verification steps when required. Coverage rules and availability can vary by medication and state.

When clinically appropriate, prescriptions can be coordinated through partner pharmacies under state regulations.

Related Resources

This category page also pairs well with trusted external references and patient education. Use these to cross-check definitions and treatment terminology. They can help when reading about dermatofibrosarcoma protuberans guidelines and DFSP patient education materials.

For an evidence-based overview, see National Cancer Institute DFSP Treatment PDQ.
For labeled safety details, review FDA Imatinib Prescribing Information.

This content is for informational purposes only and is not a substitute for professional medical advice.

Browse Doctors Browse Medication

Find suitable medication for Dermatofibrosarcoma Protuberans

Gleevec

Chronic Myeloid Leukemia, Dermatofibrosarcoma Protuberans +2

Explore & speak to doctor

Frequently Asked Questions

What is Dermatofibrosarcoma Protuberans (DFSP)?
Dermatofibrosarcoma protuberans, or DFSP, is a rare skin sarcoma. It often grows slowly and can invade nearby tissue. Many cases start as a firm patch or raised lump. Diagnosis usually depends on a skin biopsy and pathology review. Treatment conversations often focus on surgery and preventing local recurrence. Some situations involve radiation or targeted therapy. A clinician can explain how DFSP differs from other soft tissue tumors.
What records help when reviewing DFSP diagnosis details?
Helpful records include the biopsy pathology report and any procedure notes. Look for sections on histology, margin status, and immunostains like CD34. If performed, genetic results may mention a COL1A1-PDGFB fusion. Imaging reports, such as MRI, can add context for deeper involvement. If using telehealth, uploading clear scans helps the clinician review details efficiently. Keep dates attached to each document for easier timeline review.
How are DFSP treatment options usually discussed?
Clinicians often start with surgery terms and goals. Common options include wide local excision and Mohs micrographic surgery for select sites. Discussions may cover reconstruction, margin assessment, and the chance of recurrence. Radiation therapy may be considered in certain scenarios, such as difficult margins. Targeted therapy, including imatinib, may come up for unresectable, recurrent, or metastatic disease. The final plan depends on tumor location, prior treatment, and specialist input.
Can Medispress telehealth help with DFSP questions?
Telehealth can be useful for organizing records and clarifying terminology. Visits take place by video in a secure app, and clinicians lead clinical decisions. A visit may help review biopsy language, imaging summaries, and follow-up questions. Some needs still require in-person care, such as surgery planning or urgent wound concerns. When clinically appropriate, a provider may coordinate prescription options through partner pharmacies, based on state requirements.
What does "CD34 positive" mean on a DFSP report?
CD34 is a protein marker that pathologists can detect with staining. Many DFSP tumors show CD34 positivity, which can support the diagnosis. It is not fully specific, so it must match the microscope pattern and clinical story. Some reports also include molecular testing, like COL1A1-PDGFB fusion, to strengthen classification. A clinician or pathologist can explain how all findings fit together and what details matter most for planning.